| Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) (NCT07603557) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2026-08-31 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (NCT07335562) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2026-08-29 |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (NCT07015242) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-11-06 |
| A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases (NCT07115745) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-09-04 |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) (NCT07015983) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-07-14 |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) (NCT06615479) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-03-12 |
| A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting (NCT06788639) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-02-04 |
| A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting (NCT06788652) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-02-04 |
| A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting (NCT06794268) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2025-02-04 |
| A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (NCT06313996) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-03-29 |
| A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) (NCT06220201) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-03-28 |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT06297226) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-03-21 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06121843) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-02-22 |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06153251) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-01-23 |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies (NCT06205290) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-01-16 |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) (NCT05869955) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2023-09-13 |